GLPG Galapagos NV

85.99
0  0%
Previous Close 86.14
Open 86.58
Price To book 4.95
Market Cap 3.98B
Shares 46,256,000
Volume 221,323
Short Ratio 5.39
Av. Daily Volume 150,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial announced April 25, 2017.
Filgotinib
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 initiated August 2016.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 initiated August 2016.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 2 initiation announced April 4, 2017.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2 initiation announced April 4, 2017.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 initiation announced April 4, 2017.
Filgotinib
Sjögren’s syndrome
Announced February 1, 2017 that Phase 2a dosing has commenced. Top-line data due 4Q 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 2a top-line data due 2H 2017.
GLPG1690 - FLORA
Idiopathic pulmonary fibrosis
Phase 2/3 trial initiation announced December 8, 2016.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 initiated November 2016.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 initiated August 2016
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)

Latest News

  1. Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
  2. ETFs with exposure to Galapagos NV : April 28, 2017
  3. Galapagos reports first quarter 2017 results
  4. Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus
  5. Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million
  6. Galapagos raises $338 million gross proceeds in a U.S. public offering
  7. Galapagos announces launch of proposed public offering
  8. Galapagos increases share capital through warrant exercises
  9. Galapagos doses first psoriatic arthritis patient with filgotinib
  10. Galapagos Initiates 3 Phase II Studies for Filgotinib
  11. Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
  12. The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial
  13. Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings
  14. Galapagos Begins Cystis Fibrosis Treatment Study
  15. Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
  16. Can The Uptrend Continue for Galapagos (GLPG)?
  17. Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner Gilead Sciences
  18. New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
  19. Galapagos NV :GLPG-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017